ArticleAngewandte Chemie (International ed. in English)2024
Functional Selection of Tau Oligomerization-Inhibiting Aptamers.
Open access · bronzeAbstract read
In one paragraph
Article in Angewandte Chemie (International ed. in English), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Review
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
- Engineered polymerase-mediated efficient synthesis of site-specifically functionalized RNA and 2'-modified RNA oligonucleotides via genetic alphabet expansion.Nature communications · 2026Article
- RNA-based therapeutics for Alzheimer's disease and related tauopathies: challenges and opportunities.The journal of prevention of Alzheimer's disease · 2026Review
- Advances in aptamer technology for target-based drug discovery.Journal of pharmaceutical analysis · 2026Review
- Multifunctional Nanoparticles in Traumatic Brain Injury: From Targeted Imaging and Diagnosis to Innovative Therapeutics.International journal of nanomedicine · 2026Review
- Nucleic acid therapeutics in neurodegenerative disorders: emerging technologies and clinical landscape.Molecular neurodegeneration advances · 2026Review
- Therapeutic Oligonucleotides for Neurodegenerative Diseases: Aptamer Strategies and Clay Nanoparticle-Based Delivery.Chemical record (New York, N.Y.) · 2025Review
- Probing three-dimensional cyclooctatetraene for nucleobase modification in aptamer selection.Communications chemistry · 2025Article
- The Diagnostic and Therapeutic Potential of Oligonucleotide Aptamers in Alzheimer's Disease.Cells · 2025Review
- Aptamer-Nanoconjugates as Potential Theranostics in Major Neuro-Oncological and Neurodegenerative Disorders.Pharmaceutics · 2025Review
- Engineering functionally-optimized aptamers against SARS-Cov-2 for blocking spike-ACE2 interaction and aptasensor detection.Materials today. Bio · 2025Article
- Novel strategies for targeting tau oligomers in neurodegenerative diseases.Journal of neurology · 2025Review
- Incubation with tau aggregates increases hippocampal circuit excitability and enhances long-term depression in acute mouse hippocampal slices.Frontiers in neural circuits · 2025Article
- Joining Natural and Synthetic DNA Using Biversal Nucleotides: Efficient Sequencing of Six-Nucleotide DNA.Journal of the American Chemical Society · 2024Article
- Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against α-synuclein and 2N4R tau.Bioorganic & medicinal chemistry · 2024Article
- Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies.Translational neurodegeneration · 2024Review
- Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development.Molecules (Basel, Switzerland) · 2024Review
- Omics-derived biological modules reflect tau positron emission tomography in Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 2 countries.
Bang WangDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Xiaoshu PanDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
I-Ting TengDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Xiaowei LiDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Firas KobeissyCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0002-5008-6944
Zo-Yu WuCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA.
Jiepei ZhuCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA.
Guangzheng CaiCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA.
He YanDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Xin YanDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Mingwei LiangDepartment of Biochemistry and Molecular Biology, UF Health Cancer Center, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Fahong YuDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Jianrong LuDepartment of Biochemistry and Molecular Biology, UF Health Cancer Center, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Zunyi YangFoundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, USA.
Elisa BiondiFoundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, USA.
William HaskinsGryphon Bio, Inc., 611 Gateway Blvd. Suite 120 #253, South San Francisco, CA 94080-7066, USA.ORCID 0000-0001-7972-2142
Y Charles CaoDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Steven A BennerFoundation for Applied Molecular Evolution, Firebird Biomolecular Sciences LLC, 13709 Progress Boulevard, No. 7, Alachua, FL 32615, USA.
Weihong TanDepartment of Chemistry and Department of Physiology and Functional Genomics, Center for Research at Bio/Nano Interface, Health Cancer Center, UF Genetics Institute and McKnight Brain Institute, Interdisciplinary Center for Biotechnology Research, University of Florida, Gainesville, FL 32611, USA.
Kevin K WangCenter for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1458, (USA). Department of Emergency Medicine, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0002-9343-6473
University of Florida Health · USUniversity of Florida · USFirebird Biomolecular Sciences (United States) · USGryphon Scientific (United States) · USHunan University · CN
Funding
Equipment Supplement to 1R01GM141391-01A1 (Easily Used Kits to Evolve Reagents that Covalently Tag and Inactivate Proteins)R01GM141391 · NIGMS · FOUNDATION FOR APPLIED MOLECULAR EVOLUTN · PI BENNER, STEVEN A · 2021 to 2024
$1.4MNIGMS NIH HHS 1R01GM141391-01A1NIGMS NIH HHS R01 GM141391
Abstract
Pathological hyperphosphorylation and aggregation of microtubule-associated Tau protein contribute to Alzheimer's Disease (AD) and other related tauopathies. Currently, no cure exists for Alzheimer's Disease. Aptamers offer significant potential as next-generation therapeutics in biotechnology and the treatment of neurological disorders. Traditional aptamer selection methods for Tau protein focus on binding affinity rather than interference with pathological Tau. In this study, we developed a new selection strategy to enrich DNA aptamers that bind to surviving monomeric Tau protein under conditions that would typically promote Tau aggregation. Employing this approach, we identified a set of aptamer candidates. Notably, BW1c demonstrates a high binding affinity (K
Indexed as
Alzheimer DiseaseTauopathiestau ProteinsAptamers, NucleotideHumansNeuronsOkadaic AcidPhosphorylationAptamers, NucleotideOkadaic Acidtau ProteinsAptamerFunctional SelectionTauopathy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.